Press Releases

Press Releases

Morphic Announces Participation in Upcoming Investor Conferences

November 16, 2021
WALTHAM, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation in the upcoming investor conferences: Dr. Bruce N.

Morphic to Participate in Jefferies IBD Therapeutics Summit

October 12, 2021
WALTHAM, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of the Morphic leadership team are scheduled to take part

Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021

July 2, 2021
Call to discuss positive results from Phase 1 trial of MORF-057 to be presented at ECCO 2021 Virtual Congress WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of
Displaying 1 - 10 of 21